article18 January 2024 | By Catherine Eckford (European Pharmaceutical Review)
Challenges such as market exclusivity and patient treatment preference are expected to shape the insomnia and Gaucher disease therapy landscape in the seven major markets (7MM) in 2032, research predicts.